I am unable unable to post a link to the full article. This is just a summary review. The article discusses a review of all conventional therapy with survival statistics for each. It touches upon therapies that are in the pipeline as well as the efficacy of combination chemo therapies. 

I have the full copy. If anyone would like it please message me or email me at rettoc625@comcast.net perhaps the admins know of a way to post the paper more conveniently. 

http://www.ncbi.....d/25422073

Mary

Here is the abstract of the artile I cannot link. 

Mary

Vet Res Commun DOI 10.1007/s11259-014-9623-0 REVIEW ARTICLE

What do we know about canine osteosarcoma treatment? – review

M. Szewczyk & R. Lechowski & K. Zabielska Received: 10 September 2014 / Accepted: 13 November 2014 # The Author(s) 2014.

This article is published with open access at Springerlink.com Abstract Osteosarcoma (OSA) is the most common type of bone tumors in dogs, which has high metastasis ability. 80 % of dogs with OSA die due to lung metastasis. As a result its treatment is a challenge for veterinary practitioners. The au- thors discuss the etiology, pathogenesis and the possible risk factors of OSA. The article focuses on literature review and the study of recent advances in OSA treatment. The authors describe therapies which have significantly prolonged the lives of dogs, as well as those that have proven to be ineffec- tive. Advantages and disadvantages of limb amputation and limb-sparing surgery have been described. Authors present also the results of both single agent’s therapies with the most commonly used drugs as cisplatin, carboplatin and doxorubi- cin and compare them to the results obtained using combined chemotherapy. The use of nanotechnology as a new approach in OSA treatment in order to avoid multidrug resistance and reduce negative side effects of cytostatic drugs is presented. The main reasons of the therapies failure are also provided in this article. Keywords Osteosarcoma . Dogs . Treatment . Chemotherapy (Spodnick et al. 1992; Berg 1996; Cavalcanti et al. 2004; Morello et al. 2011). It most often appears in middle age dogs (between 6 and 10 years old) (Thompson and Pool 2002; Morello et al. 2011), but it has also been reported in 1–2 year old dogs (Brodey 1979). The topographic location is the appendicular skeleton (64 % of cases), the axial skeleton (28, 5 %) (ribs and skull) (Fig. 1) and the extraskeletal muscles (7, 5 %) (Calvacanti et al. 2004; Trost et al. 2012). Appendicular OSA appears more often in forelimbs than in hindlimbs, whereas extraskeletal OSA develops primarily in visceral organs (adrenal gland, eye, gastric ligament, ileum, kidney, liver, spleen, testicle and vagina) (Langenbach et al. 1998). Risk factors The ethiopathogenesis of OSA is unknown, but various pre- disposing factors (sex, body weight) may lead to its develop- ment. Dogs with a body weight above 40 kg are more predisposed than smaller dogs (Bergman et al. 1996). Most of the studies indicate that this neoplasm tends to affect males more often than females (Brodey and Abt 1976; Jongeward 1985; Pool 1990; Selverajah and Kirpenstein 2010). However, according to certain reports also females are predisposed. Cooley et al. (2002) indicate that there may be a correlation between castration and a higher risk of tumor development. Male and female dogs that underwent gonadectomy before 1 year of age had a one in four lifetime risk for bone sarcoma and they were significantly more likely to develop bone sarcoma than dogs that were sexually intact.